Shares of Telix Pharmaceuticals plunged 10.1% to A$16.05 on Monday after the Melbourne-based radiopharmaceutical company unveiled its largest-ever acquisition: a deal to buy Germany's ITM Isotope Technologies Munich SE worth as much as US$2.35 billion, securing a major supplier of radioactive materials used in cancer treatments and adding a late-stage drug candidate. For existing shareholders, the question is whether this transformational bet justifies the immediate pain of dilution and years of integration risk.
The Price Tag Is Bigger Than It Looks
Telix will pay US$1.65 billion upfront on a cash-free, debt-free basis, with as much as another US$700 million tied to regulatory approvals and sales milestones for ITM-11, a treatment being developed for neuroendocrine tumors.
About US$1.25 billion of the upfront consideration will be paid in Telix shares at US$11.84 apiece, while the company will assume US$302 million of ITM debt. All-in, the potential outlay exceeds twice Telix's standalone FY2026 revenue guidance of US$950–970 million.
Existing Shareholders Will Own a Smaller Slice
The 105.8 million newly issued shares mean existing Telix shareholders will own approximately 76.3% and ITM shareholders roughly 23.7% of the combined entity. That roughly 24% dilution is what's hitting the stock today — investors are recalculating what their piece of the company is now worth, and the market's early verdict is unfavorable.
The Strategic Logic: Owning the Supply Chain
ITM is the world's leading supplier of therapeutic radioisotopes and the only producer of globally scaled commercial-grade lutetium-177 — a critical ingredient in cancer-targeting radiation drugs in a field currently dominated by Novartis.
ITM's isotope production business is profitable and generates cash flow , a rarity for acquisition targets in biotech. By locking in its own supply, Telix reduces dependence on outside suppliers and positions itself to sell isotopes to competitors.
The Numbers Need to Work Fast
The combined entity is expected to generate pro forma 2026 revenue exceeding US$1.3 billion.
ITM's manufacturing business is profitable, and management expects a positive EBITDA (earnings before interest, taxes, depreciation, and amortization) contribution by 2027. But with Telix already trading at roughly 84.5x price-to-sales and still burning cash, the margin for error is razor-thin. Completion is targeted by year-end 2026, subject to shareholder and regulatory approvals — leaving months of uncertainty ahead.